15 assets in Testicular Leukemia

Therapeutic assets addressing Testicular Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Adriamycin Testicular Leukemia	Children's Oncology Group	P3	BB (64)
Cytarabine Testicular Leukemia	Children's Oncology Group	P3	BB (64)
Daunomycin Testicular Leukemia	Children's Oncology Group	P3	BB (64)
Mercaptopurine Anhydrous Testicular Leukemia	Children's Oncology Group	P3	BB (64)
Pegaspargase Testicular Leukemia	Children's Oncology Group	P3	BB (64)
Prednisone Testicular Leukemia	Children's Oncology Group	P3	BB (64)
Thioguanine Anhydrous Testicular Leukemia	Children's Oncology Group	P3	BB (64)
Vincristine Sulfate Testicular Leukemia	Children's Oncology Group	P3	BB (64)
Cyclophosphamide Testicular Leukemia	Children's Oncology Group	P3	B (63)
Dexasone Testicular Leukemia	Children's Oncology Group	P3	B (63)
Blinatumomab Testicular Leukemia	Children's Oncology Group	P3	B (60)
Calaspargase Pegol Testicular Leukemia	Children's Oncology Group	P3	B (60)
Inotuzumab Ozogamicin Testicular Leukemia	Children's Oncology Group	P3	B (60)
Methotrexate Testicular Leukemia	Children's Oncology Group	P3	B (60)
Prednisolone Testicular Leukemia	Children's Oncology Group	P3	B (60)